Related Experiment Video

Updated: Aug 20, 2026

Left Anterior Descending Coronary Artery Ligation for Ischemia-Reperfusion Research: Model Improvement via Technical Modifications and Quality Control
05:41

Left Anterior Descending Coronary Artery Ligation for Ischemia-Reperfusion Research: Model Improvement via Technical Modifications and Quality Control

Published on: December 16, 2022

Influence of treatment duration with a 600-mg dose of clopidogrel before percutaneous coronary revascularization

David E Kandzari1, Peter B Berger, Adnan Kastrati

  • 1Duke Clinical Research Institute, Durham, North Carolina, USA. kandz002@mc.duke.edu

Journal of the American College of Cardiology
|December 8, 2004
PubMed

Insights

For patients undergoing percutaneous coronary intervention (PCI), pretreatment with clopidogrel for longer than 2-3 hours did not show increased clinical benefit within 30 days. Major bleeding rates were also similar across all pretreatment durations.

Area of Science:

  • Cardiology
  • Interventional Cardiology
  • Pharmacology

Background:

  • The optimal duration of clopidogrel pretreatment before percutaneous coronary revascularization is not well-established.
  • Understanding the impact of clopidogrel pretreatment duration on early clinical outcomes is crucial for patient management.

Purpose of the Study:

  • To evaluate the clinical outcomes based on the duration of pretreatment with a 600-mg loading dose of clopidogrel.
  • To determine if longer pretreatment durations offer incremental benefits in patients undergoing percutaneous coronary intervention (PCI).

Main Methods:

  • Analysis of 2,159 patients from the ISAR-REACT trial who underwent PCI.
  • Patients were categorized by clopidogrel pretreatment duration: 2-3h, 3-6h, 6-12h, or >12h.
  • Primary endpoint: composite of death, myocardial infarction, or urgent revascularization within 30 days.

Main Results:

  • No significant differences in clinical outcomes were observed across different clopidogrel pretreatment durations.
  • The adjunctive therapy with abciximab or placebo did not alter the findings regarding pretreatment duration.
  • Major bleeding events did not differ based on the time of initial clopidogrel dosing.

Conclusions:

  • For low-to-intermediate risk patients, a pretreatment duration longer than 2-3 hours with a 600-mg clopidogrel loading dose before PCI did not provide evident incremental clinical benefit within 30 days.
  • These findings suggest that shorter pretreatment durations may be sufficient for achieving early clinical benefits.
Abstract

Related Concept Videos

Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
Pharmacokinetic–Pharmacodynamic Relationship: Duration of Dose-Effect Relationship01:14

Pharmacokinetic–Pharmacodynamic Relationship: Duration of Dose-Effect Relationship

For drugs producing a quantal response, onset occurs when plasma concentration reaches a minimum effective level (Cmin). The drug's action duration depends on how long the plasma concentration remains above Cmin.Two primary factors influence this duration: dose size and the rate of drug removal from the action site. Both depend on the drug's redistribution to poorly perfused tissues and elimination processes. A larger dose promotes rapid onset and prolongs the effect's duration.Consider a...
Time Course of Drug Effect01:14

Time Course of Drug Effect

The progression of a drug's impact can be analyzed by examining both the concentration-time course and the effect-time course. The concentration-time course is determined by the drug's half-life and is influenced by factors such as its pharmacokinetics, including absorption, distribution, metabolism, and elimination. The effect of the drug is often related to its concentration in the plasma and is calculated using the maximum drug effect and the plasma concentration that generates 50 percent of...
Pharmacokinetic–Pharmacodynamic Relationship: Influence of Elimination Half-Life on Effect Duration01:23

Pharmacokinetic–Pharmacodynamic Relationship: Influence of Elimination Half-Life on Effect Duration

Drug elimination from the body primarily occurs through metabolic and excretion pathways. Hepatic metabolism transforms lipophilic drugs into hydrophilic forms for excretion, typically via enzymatic processes classified as phase I (modification) and phase II (conjugation). Renal excretion eliminates drugs and metabolites through filtration and secretion in the kidneys. Impairment in liver or kidney function can hinder these processes, delaying drug clearance and extending the drug’s half-life.
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...